CAPTRUST Financial Advisors
KNSA icon

CAPTRUST Financial Advisors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

CAPTRUST Financial Advisors’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$331K Sell
5,173
-84
-2% -$4.36K ﹤0.01% 2507
2026
Q1 		$253K Buy
+5,257
New +$233K ﹤0.01% 2516

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

CAPTRUST Financial Advisors's KNSA Position: Q2 2026 in Review

CAPTRUST Financial Advisors reduced its Kiniksa Pharmaceuticals (KNSA) stake by 1.6% in Q2 2026, selling an estimated $4.36K and leaving 5,173 shares worth $331K. The position accounts for ﹤0.01% of the portfolio, ranked #2507.

CAPTRUST Financial Advisors first reported a position in KNSA in Q1 2026 and has held it in 2 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • CAPTRUST Financial Advisors held 5,173 shares of Kiniksa Pharmaceuticals worth $331K as of Q2 2026.
  • CAPTRUST Financial Advisors sold 84 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $4.36K.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #2507 holding.
  • CAPTRUST Financial Advisors first reported a position in Kiniksa Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.